➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,320,853

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,320,853 protect, and when does it expire?

Patent 9,320,853 protects BYDUREON PEN and is included in one NDA.

This patent has seven patent family members in six countries.

Summary for Patent: 9,320,853
Title:Method for administering a fluid active substance from a multi-chamber ampoule
Abstract: An administering device for administering an active substance from a multi-chamber container comprising a first chamber holding a solid active substance and a second chamber holding a dissolving liquid for the active substance, wherein the administering device comprises a mixing device for mixing the active substance with the dissolving liquid and a housing accommodating the mixing device, the container being moveable relative to the housing, and the administering device further comprising a first indicator for indicating a position of the container relative to the housing upon completion of a mixing step, and a second indicator for indicating a position of the container relative to the housing upon completion of a venting step.
Inventor(s): Galbraith; Sofia (Solothurn, CH), Moser; Ulrich (Heimiswil, CH), Hirschel; Juerg (Aarau, CH), Thompson; Ian (Burgdorf, CH)
Assignee: TecPharma Licensing AG (Burgdorf, CH)
Application Number:13/862,871
Patent Claim Types:
see list of patent claims
Use; Device;

Drugs Protected by US Patent 9,320,853

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca Ab BYDUREON PEN exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-002 Feb 28, 2014 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,320,853

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2007 016 811Apr 5, 2007

International Family Members for US Patent 9,320,853

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 101687080   Start Trial
Germany 102007016811   Start Trial
European Patent Office 2134392   Start Trial
Japan 2010523183   Start Trial
Japan 5222353   Start Trial
Poland 2134392   Start Trial
World Intellectual Property Organization (WIPO) 2008122360   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.